Fluidigm | GenomeWeb

Fluidigm

The firm reported preliminary declining revenues for both the fourth quarter and full-year 2016 reporting periods. 

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

The partners have opened a new biorepository that will engage with clinical researchers and foster future personalized medicine efforts in the German capital.

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

The partners will co-market the GenomOncology GO Clinical Workbench to interpret data generated using Fluidigm's Juno NGS library prep workflow.

Sales of Helios instruments and genomics analytical consumables were lower than expected, pulling down revenues.

The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.

The South San Francisco, California-based firm said instrument revenues fell 39 percent, driven by lower-than-average sales of its Helios mass cytometry system.

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

Instrument sales, especially the C1 sample prep platform, drove down revenues, though consumables revenue grew 4 percent year over year.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.